UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 2170-10
Program Prior Authorization/Medical Necessity
Medication Continuous glucose monitors, sensors and transmitters (all brands)
P&T Approval Date 7/2019, 10/2019, 11/2019, 3/2020, 6/2021, 2/2022, 6/2022, 2/2023,
8/2023, 7/2024
Effective Date 10/1/2024
1. Background:
Continuous glucose monitors may be used by patients with diabetes who require glucose
monitoring beyond what can be achieved with a standard blood glucose monitor. Coverage
will be provided for the Guardian Connect sensor and transmitter when the Dexcom or
Freestyle Libre monitors are not appropriate for the patient.
2. Coverage Criteriaa:
A. Initial Authorization
1. Guardian Connect, Guardian 3 and Guardian 4 continuous glucose sensors and
transmitters will be approved for initial therapy based on all of the following criteria:
a. Diagnosis of diabetes
-AND-
b. All of the following:
(1) Patient is motivated and knowledgeable about use of continuous glucose
monitoring
-AND-
(2) Patient is adherent to diabetic treatment plan
-AND-
(3) Patient participates in ongoing education and support
-AND-
c. One of the following:
(1) Patient is on an intensive insulin regimen (3 or more insulin injections per day
or uses continuous subcutaneous insulin infusion pump)b
-OR-
© 2024 UnitedHealthcare Services, Inc.
1
(2) One of the following:
(a) Patient has a history of a level 3 hypoglycemic event
(b) Patient has a history of more than one level 2 hypoglycemia events that
persist despite multiple attempts to adjust medication(s) or modify diabetes
treatment plan
-AND-
d. Patient regularly monitors blood glucose 4 or more times per dayb
-AND-
e. One of the followingb:
(1) Patient has a physical or mental limitation that makes utilization of Dexcom G6
and Dexcom G7 unsafe, inaccurate or otherwise not feasible (e.g. manual
dexterity; document limitation)
-OR-
(2) Patient has a physical or mental limitation that makes utilization of Freestyle
Libre unsafe, inaccurate or otherwise not feasible (e.g. manual dexterity;
document limitation)
Authorization will be issued for 12 months.
2. All other continuous glucose monitors, sensors and transmitters will be approved for
initial therapy based on all of the following criteria:
a. Diagnosis of diabetes
-AND-
b. All of the following:
(1) Patient is motivated and knowledgeable about use of continuous glucose
monitoring
-AND-
(2) Patient is adherent to diabetic treatment plan
-AND-
(3) Patient participates in ongoing education and support
-AND-
© 2024 UnitedHealthcare Services, Inc.
2
c. One of the following:
(1) Patient is on an intensive insulin regimen (3 or more insulin injections per day or
uses continuous subcutaneous insulin infusion pump)b
-OR-
(2) One of the following:
(a) Patient has a history of a level 3 hypoglycemic event
(b) Patient has a history of more than one level 2 hypoglycemia events that
persist despite multiple attempts to adjust medication(s) or modify diabetes
treatment plan
-AND-
d. Patient regularly monitors blood glucose 4 or more times per dayb
Authorization will be issued for 12 months.
B. Reauthorizationb
1. Continuous glucose monitors, sensors and transmitters will be approved for
continuation of therapy based on the following criterion:
a. Documentation of positive clinical response
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
b In Florida, Maine, Tennessee, and Texas only, medications prescribed for diabetes may be
approved based on both of the following: 1) Provider attests use of this product is medically
necessary for the treatment of diabetes; and- 2) If applicable, clinical characteristics exist that
preclude the use of the covered preferred alternative(s) and use of the covered preferred
alternative(s) could result in worsening of patient’s condition or inadequate treatment
(document alternatives and clinical information related to worsening/inadequate treatment).
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Supply limits may be in place.
• Coverage is not provided for indications unproven per medical benefit drug policy.
© 2024 UnitedHealthcare Services, Inc.
3
4. References:
1. American Diabetes Association. Diabetes Technology: Standards of Care in Diabetes - 2023.
Diabetes Care December 2022, Vol.46, S111-S127
2. Lane AS, Mlynarczyk MA, de Veciana M, et al. Real-time continuous glucose monitoring in
gestational diabetes: a randomized controlled trial. Am J Perinatol. 2019 Jul;36(9):891-897.
3. LeRoith D, Biessels GJ, Braithwaite SS, et al. Treatment of diabetes in older adults: an Endocrine
Society clinical practice guideline. J Clin Endocrinol Metab. 2019 May 1;104(5):1520-1574.
Program Prior Authorization/Medical Necessity –Continuous glucose monitors,
sensors and transmitters
Change Control
7/2019 New Medical Necessity program.
10/2019 Removed monitor from criteria.
11/2019 Modified criteria to allow coverage for any type of diabetes.
3/2020 Added requirement that patient is knowledgeable about continuous
glucose monitors, participates in education and support, and monitors
blood glucose 3 or more times per day.
6/2021 Modified criteria to monitor blood glucose 4 or more times per day and
added criteria that patient has inadequate glycemic control despite an
intensive diabetes management.
2/2022 Added Florida, Maine, Tennessee, and Texas mandate language.
6/2022 Added criteria for all continuous glucose monitors.
2/2023 Removed Dexcom G4 and G5 since they are no longer on the market.
Added the new product Dexcom G7.
8/2023 Added Guardian 4 to criteria. Updated diabetes mandate language.
Updated references.
7/2024 Removed requirement for inadequate glycemic control. Added criteria
for hypoglycemia.
© 2024 UnitedHealthcare Services, Inc.
4